These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 32651464)
1. Spiropiperidyl rifabutins: expanded in vitro testing against ESKAPE pathogens and select bacterial biofilms. Cabal MP; Long TE; Turos E; García AB; Allen JL; Budny BG; Shaw LN J Antibiot (Tokyo); 2020 Dec; 73(12):868-872. PubMed ID: 32651464 [TBL] [Abstract][Full Text] [Related]
2. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269 [TBL] [Abstract][Full Text] [Related]
3. Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens. Lowrence RC; Ramakrishnan A; Sundaramoorthy NS; Shyam A; Mohan V; Subbarao HMV; Ulaganathan V; Raman T; Solomon A; Nagarajan S J Appl Microbiol; 2018 Feb; 124(2):408-422. PubMed ID: 29178633 [TBL] [Abstract][Full Text] [Related]
4. Rifamycin Derivatives Are Effective Against Staphylococcal Biofilms In Vitro and Elutable From PMMA. Sanchez CJ; Shiels SM; Tennent DJ; Hardy SK; Murray CK; Wenke JC Clin Orthop Relat Res; 2015 Sep; 473(9):2874-84. PubMed ID: 25896136 [TBL] [Abstract][Full Text] [Related]
5. In Vitro Synergism and Anti-biofilm Activity of Quercetin-Pivaloxymethyl Conjugate against Staphylococcus aureus and Enterococcus Species. Kim MK; Lee TG; Jung M; Park KH; Chong Y Chem Pharm Bull (Tokyo); 2018; 66(11):1019-1022. PubMed ID: 30381653 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. Barber KE; Smith JR; Raut A; Rybak MJ J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Murphy CK; Mullin S; Osburne MS; van Duzer J; Siedlecki J; Yu X; Kerstein K; Cynamon M; Rothstein DM Antimicrob Agents Chemother; 2006 Mar; 50(3):827-34. PubMed ID: 16495239 [TBL] [Abstract][Full Text] [Related]
8. A New Kind of Quinonic-Antibiotic Useful Against Multidrug-Resistant Campanini-Salinas J; Andrades-Lagos J; Gonzalez Rocha G; Choquesillo-Lazarte D; Bollo Dragnic S; Faúndez M; Alarcón P; Silva F; Vidal R; Salas-Huenuleo E; Kogan M; Mella J; Recabarren Gajardo G; Vásquez-Velásquez D Molecules; 2018 Jul; 23(7):. PubMed ID: 30029513 [TBL] [Abstract][Full Text] [Related]
10. Bacterial susceptibility in bloodstream infections: Results from China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2015-2016. Zhang F; Li Y; Lv Y; Zheng B; Xue F J Glob Antimicrob Resist; 2019 Jun; 17():276-282. PubMed ID: 30611932 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins. Kim IH; Combrink KD; Ma Z; Chapo K; Yan D; Renick P; Morris TW; Pulse M; Simecka JW; Ding CZ Bioorg Med Chem Lett; 2007 Mar; 17(5):1181-4. PubMed ID: 17189695 [TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant staphylococcus aureus and enterococcus faecium in the Tohoku district of Japan. Lutfor AB; Kikuchi T; Tokue Y; Takahashi H; Shoji S; Fujimura S; Nukiwa T; Watanabe A Chemotherapy; 1998; 44(5):318-23. PubMed ID: 9732146 [TBL] [Abstract][Full Text] [Related]
13. Synthetically Tuning the 2-Position of Halogenated Quinolines: Optimizing Antibacterial and Biofilm Eradication Activities via Alkylation and Reductive Amination Pathways. Basak A; Abouelhassan Y; Norwood VM; Bai F; Nguyen MT; Jin S; Huigens RW Chemistry; 2016 Jun; 22(27):9181-9. PubMed ID: 27245927 [TBL] [Abstract][Full Text] [Related]
14. Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: promising in vitro profile of rifabutin. Abad L; Josse J; Tasse J; Lustig S; Ferry T; Diot A; Laurent F; Valour F J Antimicrob Chemother; 2020 Jun; 75(6):1466-1473. PubMed ID: 32125419 [TBL] [Abstract][Full Text] [Related]
15. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. Mercier RC; Stumpo C; Rybak MJ J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002 [TBL] [Abstract][Full Text] [Related]
16. New bisanthraquinone antibiotics and semi-synthetic derivatives with potent activity against clinical Staphylococcus aureus and Enterococcus faecium isolates. Socha AM; LaPlante KL; Rowley DC Bioorg Med Chem; 2006 Dec; 14(24):8446-54. PubMed ID: 16979896 [TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Mercier RC; Kennedy C; Meadows C Pharmacotherapy; 2002 Dec; 22(12):1517-23. PubMed ID: 12495161 [TBL] [Abstract][Full Text] [Related]
19. N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria. Opoku-Temeng C; Naclerio GA; Mohammad H; Dayal N; Abutaleb NS; Seleem MN; Sintim HO Eur J Med Chem; 2018 Jul; 155():797-805. PubMed ID: 29957525 [TBL] [Abstract][Full Text] [Related]
20. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]